SCHEMBL4289488

SCHEMBL4289488

Cc1nc(C)c(I)c(Cl)n1

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.31
CSNK2A1 P68400 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10252220 0.86 TDP1 (0.35) TDP1CSNK2A1
SCHEMBL21509288 0.80
SCHEMBL10043017 0.79 ALDH1A1 (0.35) CSNK2A1
SCHEMBL29849046 0.75 HTT (0.33)
SCHEMBL392017 0.75 TLR8 (0.42)
SCHEMBL13452287 0.75
SCHEMBL10252579 0.75 HTT (0.33)
SCHEMBL3114591 0.75
SCHEMBL1830615 0.72 PDE10A (0.37) TDP1
SCHEMBL10376639 0.72 LMNA (0.50) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240308968-A1 FUNGICIDAL SUBSTITUTED HETEROCYCLES FMC CORP (US) 2024-09-19 US disclosed
EP-4387957-A1 FUNGICIDAL SUBSTITUTED HETEROCYCLES FMC Corporation (US) 2024-06-26 EP disclosed
CN-117836274-A Fungicidal substituted heterocyclic compounds FMC公司 2024-04-05 CN disclosed
US-11773067-B2 (Trifluoromethyl)pyrimidine-2-amine compounds ELI LILLY AND COMPANY (US) 2023-10-03 US disclosed
WO-2023023242-A1 FUNGICIDAL SUBSTITUTED HETEROCYCLES FMC CORPORATION (US) 2023-02-23 WO disclosed
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 US disclosed
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 US disclosed
EP-2797592-B1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2019-08-28 EP disclosed
EP-2797592-B1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2019-08-28 EP disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-20140242027-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE (US) 2014-08-28 US disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed
US-20110319618-A1 HETEROCYCLIC COMPOUND AND USE OF THE SAME NISHIO TETSUYA (JP) 2011-12-29 US disclosed
US-20110318305-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS MERCK SHARP & DOHME LLC 2011-12-29 US disclosed
WO-2009155448-A1 BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS LIGAND PHARMACEUTICALS INC. (US) 2009-12-23 WO disclosed
EP-0618207-B1 Substituted pyridopyrimidines as antihypertensives AMERICAN HOME PROD (US) 1999-01-07 EP disclosed
EP-0863143-A1 Intermediates useful in the production of pyridopyrimidone angiotensin AII antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 1998-09-09 EP disclosed
US-5466692-A Substituted pyridopyrimidines and antihypertensives AMERICAN HOME PRODUCTS CORPORATION (US) 1995-11-14 US disclosed
EP-0618207-A1 Substituted pyridopyrimidines as antihypertensives AMERICAN HOME PRODUCTS CORPORATION (US) 1994-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319618-A1 HETEROCYCLIC COMPOUND AND USE OF THE SAME CYP2D6, CYP2B6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 TDP1 4545/4885CSNK2A1 1832/4885
US-20110318305-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS PNP, XDH, PNPO TDP1 658/4885CSNK2A1 1709/4885
US-11773067-B2 (Trifluoromethyl)pyrimidine-2-amine compounds P2RX1, P2RX2, P2RY1 TDP1 459/4885CSNK2A1 1092/4885
US-20140242027-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS PNP, XDH, PNPO TDP1 658/4885CSNK2A1 1709/4885
US-20240308968-A1 FUNGICIDAL SUBSTITUTED HETEROCYCLES CYP1B1, CYP1A1, NOX1 TDP1 775/4885CSNK2A1 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.